Abstract PS1-10-20: Free-her: discontinuation of maintenance her-2 directed therapy in long-term survivors of metastatic her-2 positive breast cancer: a trial update
Pilot study evaluates the safe discontinuation of HER-2 therapy in long-term survivors of metastatic breast cancer, suggesting potential for less treatment burden.
Key Points
This study aims to determine if discontinuing HER-2 directed therapy is feasible for patients with long-term complete remission of metastatic HER-2 positive breast cancer.
Single-site pilot study with IRB approval
Enrolled 20 patients with stage IV HER-2 positive breast cancer in CRR for at least 36 months
Patients monitored through ctDNA testing at intervals after treatment discontinuation
14 patients enrolled with a median age of 64.5 years
Only 2 patients developed positive ctDNA post-discontinuation, indicating potential safety of therapy cessation
No deaths occurred during the trial, with a maximum follow-up of 24 months